Good Life Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 161.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 11,616 shares of the biopharmaceutical company's stock after purchasing an additional 7,171 shares during the quarter. Good Life Advisors LLC's holdings in Gilead Sciences were worth $974,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. nVerses Capital LLC purchased a new stake in Gilead Sciences during the third quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. boosted its position in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 238 shares during the period. Palisade Asset Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth $29,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Cedar Wealth Management LLC raised its position in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 160 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
A number of equities research analysts have recently issued reports on GILD shares. BMO Capital Markets increased their target price on Gilead Sciences from $85.00 to $94.00 and gave the company an "outperform" rating in a research note on Thursday. Piper Sandler reaffirmed an "overweight" rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price target for the company in a report on Monday, July 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, October 9th. Ten analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $86.37.
View Our Latest Stock Report on GILD
Shares of NASDAQ GILD opened at $87.36 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $108.84 billion, a price-to-earnings ratio of 242.67, a price-to-earnings-growth ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The business has a 50 day simple moving average of $80.80 and a 200-day simple moving average of $72.71.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.53%. Gilead Sciences's payout ratio is currently 855.56%.
In related news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of the company's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company's stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by insiders.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.